These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 25481507

  • 1. Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells.
    Rondón-Lagos M, Verdun Di Cantogno L, Rangel N, Mele T, Ramírez-Clavijo SR, Scagliotti G, Marchiò C, Sapino A.
    BMC Cancer; 2014 Dec 07; 14():922. PubMed ID: 25481507
    [Abstract] [Full Text] [Related]

  • 2. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
    Varga Z, Tubbs RR, Wang Z, Sun Y, Noske A, Kradolfer D, Bosshard G, Jochum W, Moch H, Öhlschlegel C.
    Breast Cancer Res Treat; 2012 Apr 07; 132(3):925-35. PubMed ID: 21698407
    [Abstract] [Full Text] [Related]

  • 3. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D.
    Neoplasia; 2014 Oct 07; 16(10):861-7. PubMed ID: 25379022
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.
    Schildhaus HU, Schroeder L, Merkelbach-Bruse S, Binot E, Büttner R, Kuhn W, Rudlowski C.
    Breast; 2013 Dec 07; 22(6):1066-71. PubMed ID: 24080492
    [Abstract] [Full Text] [Related]

  • 5. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
    Moelans CB, de Weger RA, van Diest PJ.
    Breast Cancer Res Treat; 2010 Feb 07; 120(1):1-7. PubMed ID: 19760503
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
    Jiang H, Bai X, Zhao T, Zhang C, Zhang X.
    Oncol Rep; 2014 Nov 07; 32(5):1889-96. PubMed ID: 25119636
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR, Shetty S, Wang Z, Rivera CL, Portier BP, Budd GT, Downs-Kelly E, Lanigan CP, Calhoun BC.
    Cancer; 2017 Jun 15; 123(12):2230-2239. PubMed ID: 28192599
    [Abstract] [Full Text] [Related]

  • 13. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
    Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O'Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI.
    J Clin Oncol; 2015 May 20; 33(15):1680-7. PubMed ID: 25897160
    [Abstract] [Full Text] [Related]

  • 14. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.
    Gunn S, Yeh IT, Lytvak I, Tirtorahardjo B, Dzidic N, Zadeh S, Kim J, McCaskill C, Lim L, Gorre M, Mohammed M.
    BMC Cancer; 2010 Jul 28; 10():396. PubMed ID: 20667129
    [Abstract] [Full Text] [Related]

  • 15. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
    Davies V, Voutsadakis IA.
    Cancer Invest; 2020 Feb 28; 38(2):94-101. PubMed ID: 31977265
    [Abstract] [Full Text] [Related]

  • 16. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
    Panvichian R, Tantiwetrueangdet A, Wongwaisayawan S, Nampoon A, Lertsithichai P, Leelaudomlipi S.
    Appl Immunohistochem Mol Morphol; 2012 Jul 28; 20(4):367-74. PubMed ID: 22417858
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
    Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS.
    Lab Invest; 2008 May 28; 88(5):491-503. PubMed ID: 18332872
    [Abstract] [Full Text] [Related]

  • 19. Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort.
    Koudelakova V, Trojanec R, Vrbkova J, Donevska S, Bouchalova K, Kolar Z, Varanasi L, Hajduch M.
    Genes Chromosomes Cancer; 2016 May 28; 55(5):409-17. PubMed ID: 26847577
    [Abstract] [Full Text] [Related]

  • 20. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.
    Halilovic A, Verweij DI, Simons A, Stevens-Kroef MJPL, Vermeulen S, Elsink J, Tops BBJ, Otte-Höller I, van der Laak JAWM, van de Water C, Boelens OBA, Schlooz-Vries MS, Dijkstra JR, Nagtegaal ID, Tol J, van Cleef PHJ, Span PN, Bult P.
    Sci Rep; 2019 Aug 12; 9(1):11679. PubMed ID: 31406196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.